ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
자궁경부암 백신 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 923억 3,000만 달러에서 2026년에는 991억 4,000만 달러로, CAGR 7.4%로 확대될 것으로 예상됩니다. 지난 수년간의 성장세는 HPV 감염 증가 추세, HPV 백신의 조기 도입, 정부의 예방접종 캠페인, 자궁경부암에 대한 인식 개선, 백신 접종 인프라 구축 등이 주요 요인으로 꼽힙니다.
자궁경부암 백신 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 1,358억 7,000만 달러에 달하고, CAGR은 8.2%를 기록할 전망입니다. 예측 기간 동안의 성장에는 백신 기술의 발전, 개발도상국의 백신 접종 범위 확대, 예방접종을 위한 민관 협력, 1회 접종형 HPV 백신의 도입, 헬스케어 분야의 의료비 지출 증가 등이 요인으로 작용할 것으로 보입니다. 예측 기간의 주요 동향으로는 HPV 백신 접종 프로그램 확대, 자궁경부암 예방에 대한 인식 증가, 차세대 HPV 백신 개발, 정부 및 NGO의 예방접종 이니셔티브, 제약회사와 생명공학 기업 간의 협력 등이 있습니다.
자궁경부암 사례의 증가 추세는 향후 몇 년 동안 자궁경부암 백신 시장의 성장을 견인할 것으로 예상됩니다. 자궁경부암은 자궁과 질 상부를 연결하는 자궁 하부(자궁경부)에 발생하는 암의 일종입니다. 자궁경부암 발생률의 증가는 인유두종바이러스(HPV) 예방접종 미흡, 비위생적인 생활습관, 자궁경부암에 대한 인식과 이해 부족에 기인하는 바가 큽니다. 자궁경부암 백신은 고위험형 HPV를 표적으로 하여 자궁경부암 예방에 매우 효과적입니다. 예를 들어, 미국의 비영리 암 지원 단체인 미국암협회(American Cancer Society)에 따르면, 2023년 1월 기준 미국에서는 1만 3,960건의 자궁경부암이 보고되었습니다. 그 결과, 자궁경부암 환자 증가가 자궁경부암 백신 시장 확대에 기여하고 있습니다.
자궁경부암 백신 분야의 주요 기업들은 환자에게 신뢰할 수 있는 솔루션을 제공하기 위해 협업과 파트너십의 중요성을 점점 더 강조하고 있습니다. 전략적 파트너십은 일반적으로 계약상의 합의를 통해 맺어지는 두 개 이상의 기업 간의 공식적인 관계를 의미합니다. 예를 들어, 2023년 6월 노르웨이에 본사를 둔 차세대 백신 개발 기업인 Nykode Therapeutics ASA는 기제형 치료용 암 백신 'VB10.16'의 개발을 추진하기 위해 Roche Holding AG와의 협력 확대를 발표했습니다. 이번 협력을 통해 VB10.16은 진행성 자궁경부암 환자를 대상으로 로슈의 면역항암제와 병용요법으로 평가될 예정입니다. 이번 제휴는 현재 치료 옵션이 제한적이고 예후가 좋지 않은 암종에 대해 새롭고 효과적인 치료 옵션을 개발할 수 있는 가능성을 가지고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별, 국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
The cervical cancer vaccine is a vaccine specifically designed to prevent the development of cervical cancer by targeting high-risk types of human papillomavirus (HPV) that are responsible for the majority of cervical cancer cases. These vaccines work by stimulating the body's immune system to produce antibodies that can identify and neutralize the HPV virus.
The primary types of cervical cancer vaccines include Cervarix, Gardasil, and Gardasil 9. Cervarix is a cervical cancer vaccine used to provide protection against specific strains of human papillomavirus (HPV) that are known to cause cervical cancer. These vaccines are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are supplied to various end users, including hospitals, biotechnology companies, academic and research organizations, and others.
Tariffs have affected the cervical cancer vaccine market by increasing the cost of imported vaccine components and raw materials, which has led to higher production expenses and limited availability in certain regions. The impact is most significant on vaccines like Gardasil and Cervarix, particularly in Asia-Pacific and African markets that rely on imports. While tariffs may slow market growth temporarily, they also encourage local manufacturing initiatives and strategic sourcing, which could enhance regional self-sufficiency and long-term market stability.
The cervical cancer vaccine market research report is one of a series of new reports from The Business Research Company that provides cervical cancer vaccine market statistics, including cervical cancer vaccine industry global market size, regional shares, competitors with a cervical cancer vaccine market share, detailed cervical cancer vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the cervical cancer vaccine industry. This cervical cancer vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cervical cancer vaccine market size has grown strongly in recent years. It will grow from $92.33 billion in 2025 to $99.14 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing prevalence of hpv infections, early introduction of hpv vaccines, government immunization campaigns, rising cervical cancer awareness, availability of vaccination infrastructure.
The cervical cancer vaccine market size is expected to see strong growth in the next few years. It will grow to $135.87 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to advancements in vaccine technology, expansion of vaccination coverage in developing regions, public-private partnerships for immunization, introduction of single-dose hpv vaccines, increasing healthcare expenditure on preventive care. Major trends in the forecast period include expansion of hpv vaccination programs, rising awareness about cervical cancer prevention, development of next-generation hpv vaccines, government and ngo initiatives for immunization, collaborations between pharmaceutical and biotech companies.
The increasing prevalence of cervical cancer cases is anticipated to drive the growth of the cervical cancer vaccine market in the coming years. Cervical cancer is a form of cancer that affects the lower portion of the uterus, known as the cervix, which connects the uterus to the upper part of the vagina. The rise in cervical cancer incidence is largely attributed to inadequate vaccination against human papillomavirus (HPV), poor hygiene practices, and limited awareness and understanding of cervical cancer. Cervical cancer vaccines are highly effective in preventing the disease by targeting high-risk strains of HPV. For example, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, 13,960 cervical cancer cases were reported in the United States. Consequently, the growing number of cervical cancer cases is contributing to the expansion of the cervical cancer vaccine market.
Leading companies involved in cervical cancer vaccines are increasingly emphasizing collaborations and partnerships to deliver dependable solutions to patients. A strategic partnership refers to a formal relationship between two or more businesses, typically established through contractual agreements to achieve shared objectives. For instance, in June 2023, Nykode Therapeutics ASA, a Norway-based next-generation vaccine developer, announced an expansion of its collaboration with Roche Holding AG to advance VB10.16, an off-the-shelf therapeutic cancer vaccine. Under this collaboration, VB10.16 is expected to be evaluated in combination with Roche's immunotherapy in patients with advanced cervical cancer. This partnership has the potential to lead to the development of a new and effective treatment option for cancers that currently have limited therapeutic alternatives and poor prognoses.
In March 2024, Halma PLC, a UK-based technology company, acquired Rovers Medical Devices for €85 million. This acquisition aims to strengthen Halma PLC's presence in the women's health segment, particularly in cervical cancer diagnostics. Rovers Medical Devices is a Netherlands-based manufacturer known for its self-sampling device that incorporates built-in features to ensure proper sample collection and provide reassurance to women.
Major companies operating in the cervical cancer vaccine market are Merck & Co Inc, GlaxoSmithKline plc, Serum Institute of India Pvt Ltd, Beijing Wantai Biological Pharmacy Enterprise Co Ltd, Walvax Biotechnology Co Ltd, Xiamen Innovax Biotech Co Ltd, THERAVECTYS, ViciniVax, Recbio, Yuxi Zerun Biotech, BioVaxys Technology Corp, Procare Health Iberia SL, R-Pharm LLC, PathoVax LLC, PT Biofarma, Instituto Butantan, Sinergium Biotech, CSL Limited, UCB SA, Bharat Biotech International Ltd
North America was the largest region in the cervical cancer vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical cancer vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cervical cancer vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cervical cancer vaccine market consists of sales of a gardiquimod, V503, silgard, and Human papillomavirus vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cervical Cancer Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cervical cancer vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cervical cancer vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cervical cancer vaccine market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Type: Cervarix; Gardasil; Gardasil 9
2) By Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End-Users: Hospital; Other End-Users
Companies Mentioned: Merck & Co Inc; GlaxoSmithKline plc; Serum Institute of India Pvt Ltd; Beijing Wantai Biological Pharmacy Enterprise Co Ltd; Walvax Biotechnology Co Ltd; Xiamen Innovax Biotech Co Ltd; THERAVECTYS; ViciniVax; Recbio; Yuxi Zerun Biotech; BioVaxys Technology Corp; Procare Health Iberia SL; R-Pharm LLC; PathoVax LLC; PT Biofarma; Instituto Butantan; Sinergium Biotech; CSL Limited; UCB SA; Bharat Biotech International Ltd
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Expansion Of Hpv Vaccination Programs
4.2.2 Rising Awareness About Cervical Cancer Prevention
4.2.3 Development Of Next-Generation Hpv Vaccines
4.2.4 Government And Ngo Initiatives For Immunization
4.2.5 Collaborations Between Pharmaceutical And Biotech Companies
5. Cervical Cancer Vaccine Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Biotechnology Companies
5.3 Academic And Research Organizations
5.4 Government Health Agencies
5.5 Clinics
6. Cervical Cancer Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Cervical Cancer Vaccine Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Cervical Cancer Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Cervical Cancer Vaccine Market Size, Comparisons And Growth Rate Analysis
7.3. Global Cervical Cancer Vaccine Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Cervical Cancer Vaccine Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Cervical Cancer Vaccine Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Cervical Cancer Vaccine Market Segmentation
9.1. Global Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cervarix, Gardasil, Gardasil 9
9.2. Global Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.3. Global Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital, Other End-Users
10. Cervical Cancer Vaccine Market Regional And Country Analysis
10.1. Global Cervical Cancer Vaccine Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Cervical Cancer Vaccine Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Cervical Cancer Vaccine Market
11.1. Asia-Pacific Cervical Cancer Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Cervical Cancer Vaccine Market
12.1. China Cervical Cancer Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Cervical Cancer Vaccine Market
13.1. India Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Cervical Cancer Vaccine Market
14.1. Japan Cervical Cancer Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Cervical Cancer Vaccine Market
15.1. Australia Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Cervical Cancer Vaccine Market
16.1. Indonesia Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Cervical Cancer Vaccine Market
17.1. South Korea Cervical Cancer Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Cervical Cancer Vaccine Market
18.1. Taiwan Cervical Cancer Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Cervical Cancer Vaccine Market
19.1. South East Asia Cervical Cancer Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Cervical Cancer Vaccine Market
20.1. Western Europe Cervical Cancer Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Cervical Cancer Vaccine Market
21.1. UK Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Cervical Cancer Vaccine Market
22.1. Germany Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Cervical Cancer Vaccine Market
23.1. France Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Cervical Cancer Vaccine Market
24.1. Italy Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Cervical Cancer Vaccine Market
25.1. Spain Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Cervical Cancer Vaccine Market
26.1. Eastern Europe Cervical Cancer Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Cervical Cancer Vaccine Market
27.1. Russia Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Cervical Cancer Vaccine Market
28.1. North America Cervical Cancer Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Cervical Cancer Vaccine Market
29.1. USA Cervical Cancer Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Cervical Cancer Vaccine Market
30.1. Canada Cervical Cancer Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Cervical Cancer Vaccine Market
31.1. South America Cervical Cancer Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Cervical Cancer Vaccine Market
32.1. Brazil Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Cervical Cancer Vaccine Market
33.1. Middle East Cervical Cancer Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Cervical Cancer Vaccine Market
34.1. Africa Cervical Cancer Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Cervical Cancer Vaccine Market, Segmentation By Type, Segmentation By Distribution Channels, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Cervical Cancer Vaccine Market Regulatory and Investment Landscape
36. Cervical Cancer Vaccine Market Competitive Landscape And Company Profiles
36.1. Cervical Cancer Vaccine Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Cervical Cancer Vaccine Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Cervical Cancer Vaccine Market Company Profiles
36.3.1. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Serum Institute of India Pvt Ltd Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Beijing Wantai Biological Pharmacy Enterprise Co Ltd Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Walvax Biotechnology Co Ltd Overview, Products and Services, Strategy and Financial Analysis
37. Cervical Cancer Vaccine Market Other Major And Innovative Companies
Xiamen Innovax Biotech Co Ltd, THERAVECTYS, ViciniVax, Recbio, Yuxi Zerun Biotech, BioVaxys Technology Corp, Procare Health Iberia SL, R-Pharm LLC, PathoVax LLC, PT Biofarma, Instituto Butantan, Sinergium Biotech, CSL Limited, UCB SA, Bharat Biotech International Ltd
38. Global Cervical Cancer Vaccine Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Cervical Cancer Vaccine Market
40. Cervical Cancer Vaccine Market High Potential Countries, Segments and Strategies
40.1 Cervical Cancer Vaccine Market In 2030 - Countries Offering Most New Opportunities
40.2 Cervical Cancer Vaccine Market In 2030 - Segments Offering Most New Opportunities
40.3 Cervical Cancer Vaccine Market In 2030 - Growth Strategies
